Development of an injectable PHBV microparticles-GG hydrogel hybrid system for regenerative medicine

last updated: 2014-12-22
ProjectRL1 - ABMR :: publications list
TitleDevelopment of an injectable PHBV microparticles-GG hydrogel hybrid system for regenerative medicine
Publication TypePapers in Scientific Journals
Year of Publication2015
AuthorsPacheco D. P., Amaral M. H., Reis R. L., Marques A. P., and Correlo V. M.
EditorsFlorence A. T.
Abstract

Uncontrollable displacements that greatly affect the concentration of active agents at the target tissues are among a major limitation of the use of microparticulate drug delivery systems (DDS). Under this context a biphasic injectable DDS combining poly(hydroxybutyrate-co-hydroxyvalerate) (PHBV) microparticles (MPs) and a gellan gum (GG) injectable hydrogel is herein proposed for the localized delivery and long-term retention of MPs carrying hydrophilic and hydrophobic model active agents. A double emulsion-solvent evaporation method was adopted to develop the PHBV MPs, carrying bovine serum albumin (BSA) or dexamethasone (Dex) as hydrophilic and hydrophobic active agents’ models, respectively. Moreover, this method was modified, together with the properties of the hydrogel to tailor the delivery profile of the active agents. Variations of the composition of the organic phase during the process allowed tuning surface topography, particle size distribution and core porosity of the PHBV MPs and, thus, the in vitro release profile of Dex but not of BSA. Besides, after embedding hydrogels of higher GG concentration led to a slower and more sustained release of both active agents, independently of the processing conditions of the microparticulate system.

JournalInternational Journal of Pharmaceutics
Volume478
Issue1
Pagination398-408
Date Published2015-01-15
PublisherElsevier
DOI10.1016/j.ijpharm.2014.11.036
URLhttp://www.sciencedirect.com/science/article/pii/S0378517314008485
KeywordsGellan Gum, Injectable hydrogel, Microparticulate systems, Polyhydroxybutyrate-co-hydroxyvalerate, regenerative medicine
RightsopenAccess
Peer reviewedyes
Statuspublished

Back to top